2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 110

Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 144

Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 345

Snap Crackle Pop: Healing the Cracks in Our Referral Process, Helping Pediatric Rheumatology Patients Get Care Sooner

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 274

Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 716

Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 713

Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 683

Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 768

Spinal Cord Syndromes Associated with Systemic Lupus Erythematous: Differentiating Lupus Myelitis, Neuromyelitis Optica, and Multiple Sclerosis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 634

Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 408

State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 623

Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 481

Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 462

Steroid Use in Pediatric Proliferative Lupus Nephritis

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 677

Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 436

Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study

Osteoarthritis – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].